Pancreatic Cancer Research

ResearcherEmory UniversityActive in the last 2 years

Juan Manuel Sarmiento

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1874-6658; OpenAlex author ID A5020547158, A5123953265, A5132578035. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 5 papers

Papers 20

  1. "Horses out of the barn": pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification for accura… Co-author DOI 10.1111/his.70099↗
  2. High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
  3. Correction: Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-26-0614↗
  4. Optimal Timing of Adjuvant Therapy in Patients with Poorly Differentiated Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19132-z↗
  5. ASO Visual Abstract: Optimal Timing of Adjuvant Therapy for Patients with Poorly Differentiated Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19311-y↗
  6. Neoadjuvant chemotherapy for pancreatic cancer and changes in the biliary microbiome. Last author DOI 10.1016/j.amjsurg.2020.09.042↗
  7. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0911↗
  8. The Path to Whipple Reconstruction for Pancreatic Adenocarcinoma: Trans-Mesocolon or Through Ligament of Treitz? Co-author DOI 10.1007/s11605-019-04377-9↗
  9. Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2020.01.004↗
  10. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Co-author DOI 10.1016/j.jgo.2019.10.012↗
  11. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Co-author DOI 10.1172/jci.insight.130362↗
  12. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Co-author DOI 10.1002/cncr.31787↗
  13. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Co-author DOI 10.1634/theoncologist.2017-0487↗
  14. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Co-author DOI 10.1002/jso.24317↗
  15. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Co-author DOI 10.1016/j.ijrobp.2016.05.010↗
  16. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Editio… Co-author DOI 10.1245/s10434-016-5093-7↗
  17. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TN… Co-author DOI 10.1245/s10434-015-4861-0↗
  18. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  19. Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. Co-author DOI 10.1016/j.ijrobp.2012.11.019↗
  20. Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth? Last author DOI 10.1111/j.1477-2574.2011.00366.x↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shishir Kumar Maithel · 15 shared papers, 2014–2026 · strength 1.65
  2. David A. Kooby · 14 shared papers, 2011–2026 · strength 1.55
  3. Bassel F. El‐Rayes · 13 shared papers, 2014–2026 · strength 1.42
  4. Mihir Maheshkumar Shah · 3 shared papers, 2026 · strength 0.83
  5. Gregory B. Lesinski · 4 shared papers, 2020–2026 · strength 0.69
  6. Theresa Wicklin Gillespie · 2 shared papers, 2026 · strength 0.60
  7. Parit T. Mavani · 2 shared papers, 2026 · strength 0.60
  8. Olatunji Boladale Alese · 4 shared papers, 2018–2026 · strength 0.49
  9. Matthew R. Farren · 3 shared papers, 2020–2026 · strength 0.46
  10. Michael B. Ware · 3 shared papers, 2020–2026 · strength 0.46
  11. Volkan N. Adsay · 6 shared papers, 2011–2026 · strength 0.45
  12. Walid Labib Shaib · 5 shared papers, 2016–2020 · strength 0.41
  13. Alyssa M. Krasinskas · 4 shared papers, 2015–2026 · strength 0.41
  14. Ganji Purnachandra Nagaraju · 2 shared papers, 2021–2026 · strength 0.36
  15. Olca Baştürk · 3 shared papers, 2015–2026 · strength 0.33
  16. Burcu Saka · 3 shared papers, 2015–2026 · strength 0.33
  17. Michelle Dian Reid · 3 shared papers, 2015–2026 · strength 0.33
  18. Pelin Bağcı · 3 shared papers, 2015–2026 · strength 0.33
  19. Maria Citarella Russell · 3 shared papers, 2020 · strength 0.33
  20. Christina Sing-Ying Wu · 3 shared papers, 2018–2020 · strength 0.26
  21. Yuchen Zhang · 1 shared paper, 2026 · strength 0.25
  22. Chrystal M Paulos · 1 shared paper, 2026 · strength 0.23
  23. Emily R. Greene · 1 shared paper, 2026 · strength 0.23
  24. Cameron J. Herting · 1 shared paper, 2026 · strength 0.23
  25. Natalie K. Horvat · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.